KPL-4 Xenograft Model Service for Breast Cancer

The KPL-4 xenograft model delivers a validated in vivo translational platform designed to evaluate candidate therapies targeting inflammatory, HER2-overexpressing breast cancers with intrinsic resistance to standard receptor-blockade regimens. Alfa Cytology provides a comprehensive, end-to-end KPL-4 xenograft model service, integrating fully authenticated cellular assets with standardized procedural and inoculation protocols to accelerate preclinical oncology drug discovery timelines.

Overview of KPL-4 Xenograft Model for Breast Cancer

The KPL-4 cell line is an exceptionally rare and highly characterized human mammary carcinoma model, clinically established as a robust tool for studying inflammatory breast cancer (IBC) and therapeutic resistance mechanisms. Originally isolated from the malignant pleural effusion of a patient with recurrent, metastatic inflammatory breast cancer, this model exhibits marked amplification and overexpression of the human epidermal growth factor receptor 2 (HER2/ERBB2) oncogene. Concurrently, KPL-4 possesses an activating PIK3CA mutation (specifically H1047R), which drives constitutive activation of the downstream PI3K/Akt/mTOR signaling cascade. Because this dual genetic profile closely mimics the clinical molecular pathology of aggressive, trastuzumab-resistant malignancies, KPL-4 xenografts serve as an indispensable preclinical matrix for validating next-generation antibody-drug conjugates (ADCs), dual tyrosine kinase inhibitors, and novel combination strategies bypassing upstream receptor blockade.

When established in vivo as a xenograft in immunodeficient mice, KPL-4 cells form solid, poorly differentiated tumors that preserve the complex histopathological microenvironment, high lymphovascular invasion traits, and distinct genomic markers of human inflammatory breast cancer.

Fig 1. EGCit ADCs exert improved antitumor effects in various xenograft models compared to conventional ADCs. (Ha SYY, et al., 2022)

Cell Line Information: KPL-4

The KPL-4 cell line maintains a stable epithelial morphology in vitro and reliably preserves its primary HER2 overexpression and PIK3CA-driven resistance signatures upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the KPL-4 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for HER2 expression and PK/PD profiling. Leveraging our expertise in HER2-positive inflammatory breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of KPL-4 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the KPL-4 xenograft model:

• Cell Culture & Quality Control: KPL-4 cells are cultivated in cell-bank-certified growth media. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on study design and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of KPL-4 cells is prepared and blended with a verified biological matrix carrier to optimize cell viability. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. KPL-4 Xenograft Model Construction Workflow

Case Study - KPL-4 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the KPL-4 xenograft model was successfully utilized to evaluate the efficacy of a novel antibody-drug conjugate candidate targeting refractory HER2-positive breast cancer. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Our Advantages

Choosing the right partner for your inflammatory HER2-positive breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation protocols ensuring uniform tumor growth and minimizing variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, HER2-positive inflammatory breast cancer using the robust KPL-4 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.